Tripartite Therapeutics

Tripartite Therapeutics, Inc. focuses on the development of proprietary protein-based, multivalent nanoparticle platform technology (or, the Tripartite Technology) for targeted delivery of therapeutics to satisfy un-met medical needs in cancer therapy, versatile subunit vaccines and immune cell-mediated therapy. The Company's nanoparticle module is... derived from stable human serum proteins and possesses the following desirable pharmaceutical properties: uniform composition, long serum half-life, biodegradability, biocompatibility, low toxicity, weak immunogenicity. In addition, it is highly expressed, assembled in and purified from E coli. By integrating nanoparticle formulation, multivalent targeting capacity and multiple therapeutics payload (both small-molecule and protein drugs) into a single entity, the technology represents a breakthrough in the field of cancer chemotherapy-that is, capable of synchronizing the pharmacokinetics and bio-distribution of multiple drugs before their entering into targeted cells-both tumor cells and their neighboring blood vessel cells as well. As a result, the long-sought synergistic efficacy of cancer-drug combination therapy becomes attainable. The unparalleled advantages offered by the Company's nanoparticle therapeutics--low toxicity arising from tumor-specific bio-distribution, MDR insensitivity and long serum half-life, in conjunction with the EPR effect typical of tumor tissues--not only reduce the number of drug administration and thus improve patient compliance, but also create, like those for chronic diseases, a long-term treatment regimen for cancers. Applications of the Company's nanoparticle platform technology can be fruitfully expanded into other fields, such as vaccine development and immune cell-mediated therapy. For vaccine development, single or multiple pathogen- or tumor-specific antigens are grafted to the nanoparticle. The extremely low immunogenicity of the Company's nanoparticle strongly accentuates the immune response against the grafted antigen. ...Read More